Jacques E. Chelly

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Jacques E. Chelly sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Jacques E. Chelly: 10 sponsored US clinical trials, 3 recruiting.

Jacques E. Chelly sponsors 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nasogastric Tube Intubation, with 1 trials.

Top-decile sponsor footprint

Jacques E. Chelly ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Vagal Stimulator to Reduce Nasogastric Tube Use

NCT06648759
RECRUITING NA

Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement

NCT05506878
RECRUITING NA

Auriculotherapy in the Treatment of Pre-Operative Anxiety

NCT04836936
NOT YET RECRUITING NA

NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty

NCT07439666
COMPLETED NA

A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery

NCT05252858
COMPLETED NA

Auriculotherapy for Surgical Pain

NCT03860259
TERMINATED Phase 2

Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery

NCT04220489
COMPLETED NA

NSS-2-BRIDGE Study for Total Knee and Hip Arthroplasties, Bariatric, and Kidney Transplant Surgeries

NCT03834142
COMPLETED NA

NSS-2 BRIDGE Device in Post-Operative Pain Management

NCT03555266
COMPLETED NA

A Pain Study Comparing Two Commonly Used Medications to Treat Pain After Bowel Surgery

NCT02849678

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Nasogastric Tube Intubation 1
Pain, Abdominal 1
Auriculotherapy 1
Liver Transplant 1
Abdominal Cancer 1
Anxiety Preoperative 1
Acute Pain 1
Cancer Pain 1
Surgery 1
Opioid Use 1

What is open in the Jacques E. Chelly pipeline

3 recruiting of 10 indexed (30% open); 5 completed (50%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Nasogastric Tube Intubation (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Jacques E. Chelly: open-pipeline peers nationwide

Peers matched on 10 registered trials and 30% open enrollment, not the therapeutic-area sidebar.

Jacques E. Chelly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Jacques E. ChellyAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsCentre hospitalier de l'Université de Montréal (CHUM)Child TrendsJason SperryMedtronic Cardiac Ablation Solutions
Jacques E. Chelly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jacques E. Chelly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 30% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Jacques E. Chelly page

10 registered trials is a research-attention snapshot, not an endorsement of Jacques E. Chelly or any single study.

  • 3 of Jacques E. Chelly's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Nasogastric Tube Intubation is the condition Jacques E. Chelly studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nasogastric Tube Intubation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Jacques E. Chelly pipeline card: 10 registered trials from official public datasets.Report a data error.